Delayed Nyse  -  05/20 04:03:19 pm EDT
52.47 USD   +3.59%
05/20Wall Street ends mixed after punishing week
05/20Rite Aid to Start Administering Pfizer's Booster Shot to Chidren Ages 5 to 11
05/20Pfizer Enters Deal to Sell COVID-19 Drug Paxlovid to Switzerland
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Canada approves Pfizer COVID drug

01/17/2022 | 01:22pm EDT

TORONTO (AP) — Canada’s health regulator has approved a pill by Pfizer that treats the effects of COVID-19.

Health Canada authorized Paxlovid for adult patients with mild or moderate COVID-19 who are also at high risk of becoming more seriously ill. Health Canada did not authorize it for use on teenagers or on patients who are already hospitalized because of COVID-19.

The agency’s announcement Monday comes amid soaring numbers of infections because of the highly transmissible omicron variant.

Late last month, U.S. health regulators authorized the pill that patients will be able to take at home to ward off the worst effects of the virus. At the time, Pfizer said it had 180,000 treatment courses available worldwide, with roughly 60,000 to 70,000 allocated to the U.S. The company said it expected to have 250,000 available in the U.S. by the end of January.

Dr. Supriya Sharma, chief medical adviser with Health Canada, said the Pfizer pill comes at a “crucial time in the pandemic as we’re faced with new variants.” The drug could help alleviate pressure on health-care systems by decreasing the number of people who would require hospitalization, but health officials noted on a conference call Monday that supply would be an issue early on.

Sharma said clinical trials showed treatment with Paxlovid reduced the risk of hospitalization and death caused by COVID-19 by 89% when the medications were started within three days of the beginning of symptoms, and by 85% when started within five days.

Copyright 2022 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission., source Associated Press News

All news about PFIZER, INC.
05/20Wall Street ends mixed after punishing week
05/20Rite Aid to Start Administering Pfizer's Booster Shot to Chidren Ages 5 to 11
05/20Pfizer Enters Deal to Sell COVID-19 Drug Paxlovid to Switzerland
05/20Pfizer's Xeljanz Recommended By European Medicines Agency Committee to Treat Ankylosing..
05/20Switzerland Secures Order for Pfizer's Antiviral COVID-19 Drug Paxlovid
05/20EU Member States Seek Changes To Supply Contracts For COVID-19 Jabs Amid Declining Dema..
05/19US Health Agency Approves Pfizer-BioNTech's COVID-19 Booster Jab For Children
05/19CDC urges Pfizer booster for children ages 5 to 11
05/19EU health regulator backs using AstraZeneca COVID shot as booster
05/19Thinking about trading options or stock in Tesla, Microsoft, Walt Disney, NVIDIA, or Pf..
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 104 B - -
Net income 2022 35 662 M - -
Net cash 2022 10 478 M - -
P/E ratio 2022 8,75x
Yield 2022 3,09%
Capitalization 294 B 294 B -
EV / Sales 2022 2,73x
EV / Sales 2023 3,58x
Nbr of Employees 79 000
Free-Float 58,2%
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 52,47 $
Average target price 57,79 $
Spread / Average Target 10,1%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-11.14%294 404
JOHNSON & JOHNSON1.68%465 705
ABBVIE INC.11.53%266 851
ROCHE HOLDING AG-15.67%266 707
NOVO NORDISK A/S3.58%245 099